Synergistic effect of interleukin 1 and soluble CD23 on the growth of human CD4+ bone marrow-derived T cells.
Low-affinity Fc epsilon receptor (Fc epsilon RII/CD23) is expressed by various human cells and known to be cleaved into soluble fragments (sCD23). Several biological activities were ascribed to these molecules. In this study, we have assessed the effect of recombinant 25-kDa sCD23 (rsCD23) on human bone marrow-derived T cells. Our results show that rsCD23 in synergy with recombinant interleukin 1 enhances mitogenic responsiveness of CD4+ T cells but does not affect CD8+ cell growth. Furthermore, rsCD23 synergizes autologous marrow cells in enhancement of CD4+ cell growth while CD23 monoclonal antibodies decrease accessory cell effect. Together, these data confirm cytokine-like activity of sCD23 on human T cell lineage.
Bertho
J M
JM
Laboratoire d'Immunologie, CNRS URA 186, CHU Pitié-Salpêtrière, Paris, France.
Fourcade
C
C
Dalloul
A H
AH
Debré
P
P
Mossalayi
M D
MD
D000944:Antigens, Differentiation, B-Lymphocyte / Q000502:physiology*; D001854:Bone Marrow Cells; D015704:CD4 Antigens / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D011961:Receptors, Fc / Q000502:physiology*; D017455:Receptors, IgE; D011994:Recombinant Proteins / Q000494:pharmacology
D000944:Antigens, Differentiation, B-Lymphocyte; D015704:CD4 Antigens; D007375:Interleukin-1; D011961:Receptors, Fc; D017455:Receptors, IgE; D011994:Recombinant Proteins